MoonLake's Sonelokimab Meets All Endpoints In Phase 3 PsA Trial
MoonLake Immunotherapeutics (MLTX) reported topline Phase 3 IZAR-1 results for Sonelokimab in biologic-naive adults with active psoriatic arthritis. The trial met the Week 16 primary endpoint, with 42.1% on 60 mg achieving ACR50. Secondary results included 66.5% ACR20, 41.2% MDA, and 61% PASI90. Safety showed no new signals. Full readout is expected in H1 2026.
How this was made
The 30-second read
Why it matters
The article discloses new Phase 3 topline efficacy and safety signals at Week 16, plus a roadmap for continued follow-up (Week 52 durability) and additional catalysts (IZAR-2 completion, P-OLARIS results, and planned HS BLA submission).
Market read
For MLTX traders, the key new information is the Week 16 Phase 3 IZAR-1 topline efficacy package and the stated absence of new safety signals, which can re-rate the probability of success ahead of later readouts.
What to watch
Investors should watch Week 52 durability, any subgroup performance, and how IZAR-2 (TNF-refractory) and the planned HS BLA timeline affect perceived probability-weighted value.
Background
MoonLake is advancing sonelokimab, a nanobody targeting IL-17A and IL-17F, in a Phase 3 program (IZAR-1 and IZAR-2) for psoriatic arthritis.
Ticker impact
MoonLake reported Phase 3 IZAR-1 topline success for sonelokimab, meeting the Week 16 primary endpoint with ACR50 42.1% at 60 mg.
Near-term upside bias on continued biotech risk appetite, with volatility likely as investors price in H1 2026 full readout and later IZAR-2/other program milestones.
The article provides multiple efficacy endpoints (ACR50/20, MDA, PASI90) and states no new safety signals, which are meaningful for valuation. However, it is topline only, with durability and full dataset still pending.
Market effects
Reinforces IL-17A/IL-17F pathway competitiveness in psoriatic arthritis and may lift sentiment for next-gen biologics/nanobody approaches.
Limited direct regional spillover; primarily impacts US-listed biotech sentiment and clinical-stage IL-17 peers.
Could influence global PsA treatment landscape expectations, but magnitude depends on durability and regulatory interpretation of topline endpoints.
Counterpoint
Topline success may not translate into durable benefit or differentiated safety versus existing IL-17/IL-23 options, so the market may over-discount the remaining Phase 3 readouts.
Key entities
- companyMoonLake Immunotherapeutics
Sponsor of the Phase 3 IZAR-1 trial for sonelokimab in biologic-naïve adults with active psoriatic arthritis.
- drugSonelokimab
Nanobody targeting IL-17A and IL-17F, evaluated in Phase 3 IZAR-1 and other inflammatory indications.
- clinical_trialIZAR-1 trial
Phase 3 randomized, double-blind, placebo-controlled study; met primary endpoint at Week 16 per topline results.
